Business Wire

CA-CAVLI-WIRELESS

26.3.2024 10:21:33 CET | Business Wire | Press release

Share
Cavli Wireless All Set to Introduce the 5G RedCap CQM220 Cellular IoT Module at Embedded World 2024

Cavli Wireless, a pioneer in the IoT solutions landscape, is all set to announce its flagship 5G RedCap CQM220 Cellular IoT Module at Embedded World 2024. The event, held at the NürnbergMesse GmbH, Nürnberg, Germany, from April 9 to 11 in Hall 3, Booth 3-311. Embedded World event is known for being the largest trade fair for Embedded technology, showcasing the latest and greatest in electronic systems, distributed intelligence, IoT, energy efficiency, and more. The event represents the premier stage for global innovators like Cavli Wireless to showcase the innovative CQM220 to the world.

The CQM220 is the flagship 5G RedCap cellular IoT module from Cavli Wireless, compatible with 3GPP release 17 standards, specifically designed for advanced IoT and M2M applications. It delivers robust data bandwidth, reaching up to 226Mbps in downlink and 121Mbps in uplink, facilitating rapid and efficient data transfer. Available in LGA, PCIe Gen2, and M.2 form factors, the CQM220 ensures broad compatibility and flexibility across various industrial applications. Its optional integrated eSIM offers global connectivity through the Cavli Hubble Device and Connectivity management platform, making it a versatile solution for international deployment.

Moreover, the CQM220's optional integrated GNSS feature positions it as an ideal candidate for precise tracking applications, essential in sectors like Asset Tracking and Vehicular Telemetry Systems. Accompanied by a Linux-based OpenSDK, the module allows for application-specific coding directly on the device, eliminating the need for an external host MCU. This capability, combined with its high data throughput and global operability, makes the CQM220 an optimal choice for next-generation applications that demand speed, accuracy, and worldwide functionality.

The CQM220 module is set to supercharge a range of industries with its advanced connectivity. In Industry 4.0, the module's high data throughput, and integrated GNSS make it a linchpin for smart factories, facilitating real-time monitoring and control of machinery, and predictive maintenance, thereby enhancing efficiency and reducing downtime. For Smart City initiatives, the CQM220's global connectivity and robust bandwidth support the deployment of smart grids, intelligent transportation systems, and public safety networks, contributing to more efficient and responsive urban environments. In asset tracking, the precision of the integrated GNSS and the module's widespread connectivity ensure accurate, real-time location tracking of goods and equipment across borders, which is crucial for logistics, fleet management, and theft prevention. Across these applications, the CQM220 empowers industries to harness the full potential of seamless global connectivity, driving innovation and operational excellence.

The Cavli Hubble Stack further enhances the capabilities of the CQM220 by introducing remote diagnosis, monitoring, and debugging of the module through Hubble Lens, an advanced component of the Cavli Hubble IoT connectivity & modem management platform. This feature eliminates the necessity for physical intervention, simplifying the expansion of IoT solutions. Through strategic alliances with operators worldwide, Cavli has established a substantial presence, delivering unparalleled connectivity solutions that set new standards in service quality and cost-effectiveness.

John Mathew, the CEO and the Chief Technology Architect of Cavli Wireless, remarked, "Unveiling the CQM220 at Embedded World 2024 marks a pivotal point for our company. Our continuous commitment to superior performance and creativity in the field of intelligent cellular connections has culminated in the creation of this durable 5G RedCap module. It is characterized by its dependability, effectiveness, and the ability to provide uninterrupted connectivity worldwide. These features are the core aspects of the CQM220 and serve to set apart both the product and Cavli Wireless in the bustling market."

With the unveiling of the CQM220 at Embedded World 2024, Cavli Wireless reiterates its dedication to providing cost-effective, uninterrupted, and superior cellular IoT solutions. We encourage you to engage with our solution specialists to explore the ways the CQM220 can enhance your upcoming project. Embark on your path to dependable and effective connectivity with Cavli.

About Cavli Wireless

Cavli Wireless is a cellular IoT module manufacturer that combines IoT connectivity and data management into one platform. Cavli designs and manufactures industrial-grade cellular IoT smart modules that improve equipment reliability and expedite application development processes. Cavli's smart cellular modules are equipped with global cellular connectivity through integrated eSIM functionality that provides users with affordable global data pricing, simplified device management, and centralized subscription management through the proprietary cloud-based platform Cavli Hubble.

About Embedded World

The Embedded World Exhibition & Conference is a global platform for the embedded systems community, where professionals from around the world can connect and share knowledge. The event offers insights into the entire world of embedded systems, including hardware, software, tools, and services. It features a high-quality transfer of knowledge through top-class speakers, expert panels, and exhibitor forums.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240326234488/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye